Skip to main content
    D

    DiaMedica Therapeutics Inc (DMAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.33
    -0.46 (-5.23%)

    Market Cap: $474.29M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    DiaMedica Therapeutics Inc (DMAC) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    DiaMedica Therapeutics (DMAC) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, DiaMedica Therapeutics reported EPS of -$0.21, below the -$0.20 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(19/38)
    Avg Surprise
    +1.49%

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.23
    Range-$0.25 - -$0.20
    6 analysts
    Revenue Consensus
    N/A
    RangeN/A
    6 analysts

    Next Report

    DMAC has an expected report date of Mar 29, 2027.

    DMAC Earnings Call

    The latest DMAC earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, DMAC beat 19, missed 14 and matched 5. The widest gap in the table came in the quarter ended Jun 30, 2018, when EPS landed 275.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.21-$0.20-$0.23 - -$0.19-5.00%MissN/A41 up, 0 downNov 12, 2026
    Jun 30, 2026-$0.19-$0.19-$0.21 - -$0.190.00%In lineN/A42 up, 1 downAug 10, 2026
    Mar 31, 2026-$0.19-$0.18-$0.20 - -$0.17-5.56%MissN/A42 up, 1 downMay 6, 2026
    Dec 31, 2025-$0.17-$0.18-$0.20 - -$0.17+2.86%BeatN/A40 up, 3 downMar 30, 2026
    Sep 30, 2025-$0.17-$0.16-$0.17 - -$0.15-6.25%MissN/A33 up, 0 downNov 12, 2025
    Jun 30, 2025-$0.18-$0.19-$0.22 - -$0.17+5.26%BeatN/A30 up, 2 downAug 12, 2025
    Mar 31, 2025-$0.18-$0.18-$0.19 - -$0.170.00%In lineN/A30 up, 0 downMay 13, 2025
    Dec 31, 2024-$0.18-$0.17-$0.18 - -$0.16-4.35%MissN/A41 up, 2 downMar 17, 2025
    Sep 30, 2024-$0.15-$0.15-$0.19 - -$0.130.00%In lineN/A40 up, 0 downNov 13, 2024
    Jun 30, 2024-$0.13-$0.16-$0.16 - -$0.15+18.75%BeatN/A31 up, 0 downAug 7, 2024
    Mar 31, 2024-$0.14-$0.16-$0.16 - -$0.15+12.50%BeatN/A30 up, 0 downMay 8, 2024
    Dec 31, 2023-$0.14-$0.14-$0.14 - -$0.140.00%In lineN/A30 up, 0 downMar 19, 2024
    Sep 30, 2023-$0.12-$0.13-$0.14 - -$0.11+7.69%BeatN/A30 up, 0 downNov 13, 2023
    Jun 30, 2023-$0.16-$0.18-$0.22 - -$0.15+11.11%BeatN/A30 up, 0 downAug 14, 2023
    Mar 31, 2023-$0.20-$0.16-$0.18 - -$0.14-25.00%MissN/A30 up, 0 downMay 15, 2023
    Dec 31, 2022-$0.14-$0.14-$0.18 - -$0.120.00%In lineN/A30 up, 0 downMar 28, 2023
    Sep 30, 2022-$0.12-$0.15-$0.18 - -$0.12+20.00%BeatN/A41 up, 0 downNov 9, 2022
    Jun 30, 2022-$0.13-$0.18-$0.23 - -$0.15+27.78%BeatN/A41 up, 0 downAug 10, 2022
    Mar 31, 2022-$0.13-$0.21-$0.32 - -$0.15+38.10%BeatN/A30 up, 0 downMay 4, 2022
    Dec 31, 2021-$0.11-$0.18-$0.22 - -$0.14+38.89%BeatN/A50 up, 0 downMar 14, 2022
    Sep 30, 2021-$0.18-$0.23-$0.34 - -$0.19+21.74%BeatN/A61 up, 0 downNov 10, 2021
    Jun 30, 2021-$0.17-$0.22-$0.33 - -$0.17+22.73%BeatN/A6N/AAug 11, 2021
    Mar 31, 2021-$0.19-$0.22-$0.28 - -$0.15+13.64%BeatN/A6N/AMay 5, 2021
    Dec 31, 2020-$0.23-$0.17-$0.21 - -$0.13-35.29%MissN/A5N/AMar 10, 2021
    Sep 30, 2020-$0.19-$0.15N/A-26.67%MissN/AN/AN/ANov 4, 2020
    Jun 30, 2020-$0.17-$0.13N/A-30.77%MissN/AN/AN/AAug 11, 2020
    Mar 31, 2020-$0.19-$0.28N/A+32.14%BeatN/AN/AN/AMay 13, 2020
    Dec 31, 2019-$0.21-$0.25N/A+16.00%BeatN/AN/AN/AMar 23, 2020
    Sep 30, 2019-$0.20-$0.21N/A+4.76%BeatN/AN/AN/ANov 13, 2019
    Jun 30, 2019-$0.21-$0.26N/A+19.23%BeatN/AN/AN/AAug 13, 2019
    Mar 31, 2019-$0.27-$0.20N/A-35.00%MissN/AN/AN/AMay 13, 2019
    Dec 31, 2018-$0.23-$0.20N/A-15.00%MissN/AN/AN/AMar 19, 2019
    Sep 30, 2018-$0.07-$0.16N/A+56.25%BeatN/AN/AN/ANov 19, 2018
    Jun 30, 2018-$0.60-$0.16N/A-275.00%MissN/AN/AN/AAug 29, 2018
    Mar 31, 2018-$0.20-$0.16N/A-25.00%Miss-200.0%N/AN/AApr 30, 2018
    Sep 30, 2017-$0.17-$0.16N/A-6.25%MissN/AN/AN/ANov 27, 2017
    Jun 30, 2017-$0.20-$0.14N/A-42.86%MissN/AN/AN/AAug 29, 2017
    Mar 31, 2017$0.20-$0.16N/A+225.00%BeatN/AN/AN/AApr 27, 2017
    Sep 30, 2016-$0.20N/AN/AN/AN/AN/AN/AN/ANov 29, 2016
    Jun 30, 2016-$0.12N/AN/AN/AN/AN/AN/AN/AAug 29, 2016
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.70, after -$0.60 the year before. It was -$2.28 for the year ended Dec 31, 2012, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.70N/A
    Dec 31, 2024-$0.60N/A
    Dec 31, 2023-$0.62N/A
    Dec 31, 2022-$0.52N/A
    Dec 31, 2021-$0.65N/A
    Dec 31, 2020-$0.78N/A
    Dec 31, 2019-$0.89N/A
    Dec 31, 2018-$5.83N/A
    Dec 31, 2012-$2.28N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,200 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,2118
    2026Q2Jun 30, 20263,9459
    2026Q1Mar 31, 20263,2128
    2025Q4Dec 31, 20254,1919
    2025Q3Sep 30, 20252,9438
    2025Q2Jun 30, 20252,7666
    2025Q1Mar 31, 20252,4536
    2024Q4Dec 31, 20243,9838

    2026Q3 Earnings Call

    Opening remarks

    Rick Pauls President and CEO Thank you, operator, and good morning, everyone. Thank you for joining our third quarter earnings call. With me today are Dr. Julie Krop, our chief medical officer, and Scott Kellen, our chief financial officer. Since our last earnings call, we achieved two major clinical milestones. First, enrollment was completed in the first two cohorts of the investigator-sponsored phase 2 early-onset fetal growth restriction study. Second, in October, we enrolled the 200th participant in ReMEDy2, our pivotal phase 2/3 trial in acute ischemic stroke. With this, we attained the prespecified enrollment threshold required for the ReMEDy2 interim analysis. Together, these milestones bring us closer to important clinical readouts that could help define the next stage of development for DM199 in fetal growth restriction, preeclampsia, and acute ischemic stroke. We are also continuing to prepare for additional studies in preeclampsia, including our company-sponsored phase 2 trial, and made progress addressing FDA feedback on the nonclinical package needed for a U.S. investigational new drug application for preeclampsia. I will walk through the major updates. Julie will discuss the clinical objectives in more detail, and Scott will review our financial results. As a reminder, DM199, generic name rinbifetapenem alfa, is a recombinant form of human tissue kallikrein-1, or KLK1. Through activation of the bradykinin-2 receptor pathway, we believe DM199 has the potential to improve vascular health and function, ultimately improving blood flow. This is a completely novel mechanism of action and provides a common therapeutic rationale across preeclampsia, fetal growth restriction, acute ischemic stroke, and other diseases, even though the clinical objectives and endpoints differ across these indications. Let me begin with the early-onset fetal growth restriction program, or FGR. Professor Cluver has now completed enrollment in the first two cohorts of the phase 2 study being conducted at Tygerberg Hospital in Cape Town, South Africa. Together, these cohorts include 12 participants, with six treated at 5 micrograms per kg and six treated at 10 micrograms per kg. This is the first clinical evaluation of DM199 in women with early-onset fetal growth restriction. Early-onset FGR is a pregnancy disorder associated with significant risks to the fetus, frequently resulting from placental insufficiency, creating impaired blood flow that restricts the supply of oxygen and nutrients to the baby. Currently, no therapy is approved to treat FGR. The only option today for physicians is to closely monitor both mother and baby, balancing the risk of stillbirth and fetal complications from worsening placental function against the serious neonatal risk of delivering very prematurely. In pregnancies complicated by preeclampsia, maternal risk also includes severe hypertension and organ injury.

    Frequently Asked Questions About DMAC

    When is DiaMedica Therapeutics's next earnings date?

    DiaMedica Therapeutics's next earnings report is expected for Mar 29, 2027.

    Did DMAC beat earnings estimates last quarter?

    No. DiaMedica Therapeutics reported EPS of -$0.21 for the quarter ended Sep 30, 2026, below the -$0.20 estimate by 5.00%.

    What EPS do analysts expect from DMAC next quarter?

    The consensus EPS estimate for DiaMedica Therapeutics for the quarter ending Dec 31, 2026 is -$0.23 from 6 analysts, with estimates from -$0.25 to -$0.20.

    How often does DMAC beat earnings estimates?

    DiaMedica Therapeutics beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -1.63%.